文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

工程化分枝杆菌噬菌体TM4::GeNL快速测定结核分枝杆菌临床分离株对贝达喹啉、普托马尼、利奈唑胺、利福平和氯法齐明的敏感性

Engineered Mycobacteriophage TM4::GeNL Rapidly Determines Bedaquiline, Pretomanid, Linezolid, Rifampicin, and Clofazimine Sensitivity in Mycobacterium tuberculosis Clinical Isolates.
PubMed 文献 · J Infect Dis · 2025-01-01

本研究开发了一种基于荧光素酶报告的分枝杆菌噬菌体药敏试验,可在48小时内确定结核分枝杆菌对贝达喹啉、普托马尼、利奈唑胺、氯法齐明和利福平的耐药性。采用53株临床分离株进行原理验证,TM4::GeNL噬菌体药敏试验能有效区分敏感与耐药菌株,并识别出MGIT药敏试验分类为敏感的低水平利福平耐药。

要点

  • TM4::GeNL噬菌体药敏试验可在48小时内确定结核分枝杆菌对贝达喹啉、普托马尼、利奈唑胺、氯法齐明和利福平的敏感性。
  • 在53株临床分离株中,该试验在贝达喹啉和利福平0.125 μg/mL浓度下有效区分敏感与耐药菌株。
  • 该试验可识别MGIT药敏试验分类为敏感的低水平利福平耐药临床分离株。

核心结论

  • TM4::GeNL报告噬菌体药敏试验提供了一种快速鉴定结核分枝杆菌耐药性的方法,包括对新型抗结核药物的耐药性。

研究设计与样本

  • 研究开发了表达绿色增强纳米荧光素酶(GeNL)盒的TM4分枝杆菌噬菌体,并针对贝达喹啉、普托马尼、利奈唑胺、氯法齐明和利福平优化了药敏试验。
  • 采用53株临床结核分枝杆菌分离株进行原理验证研究。

主要发现

  • TM4::GeNL噬菌体药敏试验在贝达喹啉和利福平浓度为0.125 μg/mL时有效区分敏感与耐药分离株。
  • 对普托马尼、氯法齐明和利奈唑胺,区分敏感与耐药分离株的最佳浓度分别为0.5 μg/mL、0.25 μg/mL和1 μg/mL。
  • TM4::GeNL药敏试验识别出MGIT药敏试验分类为敏感的低水平利福平耐药临床分离株。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Drug-resistant tuberculosis is a growing public health threat, and early characterization of the resistance phenotype is essential for guiding treatment and mitigating the high mortality associated with the disease. However, the slow growth rate of Mycobacterium tuberculosis, the causative agent of tuberculosis, necessitates several weeks for conventional culture-dependent drug susceptibility testing (DST). In addition, there are no widely available molecular diagnostic assays for evaluating resistance to newer tuberculosis drugs or drugs with complex resistance mechanisms. METHODS: We have developed a luciferase-based reporter mycobacteriophage assay that can determine drug resistance within 48 hours. We engineered the TM4 mycobacteriophage to express green enhanced nanoluciferase (GeNL) cassette and optimized DST for bedaquiline, pretomanid, linezolid, clofazimine, and rifampicin using clinical M. tuberculosis isolates. RESULTS: To assess the feasibility of this assay, we conducted a proof-of-principle study using 53 clinical M. tuberculosis isolates. TM4::GeNL phage DST effectively distinguished between sensitive and resistant isolates for bedaquiline and rifampicin at a concentration of 0.125 μg/mL. Optimal differentiation between sensitive and resistant isolates for pretomanid, clofazimine, and linezolid was achieved at concentrations of 0.5 μg/mL, 0.25 μg/mL, and 1 μg/mL, respectively. Additionally, TM4::GeNL DST identified low-level rifampicin resistance in clinical isolates even though they were classified as sensitive by Mycobacteria Growth Indicator Tube DST. CONCLUSIONS: TM4::GeNL reporter phage DST offers a rapid method to identify M. tuberculosis drug resistance, including resistance to newer tuberculosis drugs.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Rajagopalan S, Rourke AK, Asare E, et al. Engineered Mycobacteriophage TM4::GeNL Rapidly Determines Bedaquiline, Pretomanid, Linezolid, Rifampicin, and Clofazimine Sensitivity in Mycobacterium tuberculosis Clinical Isolates. J Infect Dis. 2025. PMID: 39412357. doi:10.1093/infdis/jiae438

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。